医学
德诺苏马布
前列腺癌
唑来膦酸
骨质疏松症
不利影响
内科学
雄激素剥夺疗法
肿瘤科
泌尿科
癌症
作者
Aaron P. Mitchell,David Nemirovsky,Akriti Mishra Meza,Nirjhar Chakraborty,Sonia Persaud,Azeez Farooki,Michael J. Morris
摘要
Bone-modifying agents (BMAs) do not prevent skeletal-related events among patients with castration-sensitive prostate cancer (CSPC), but many patients receive BMAs unnecessarily. The costs to Medicare from overuse have not been assessed.
科研通智能强力驱动
Strongly Powered by AbleSci AI